Open Access

Co-Existence of CYP2C19*1/*2 and ABCB1c.3435 CT Genotype has a Potential Impact on Clinical Outcome in CAD Patients Treated with Clopidogrel

KA Nestorovska
KA Nestorovska
, 
Z Naumovska
Z Naumovska
, 
M Staninova Stojovska
M Staninova Stojovska
, 
Z Sterjev
Z Sterjev
, 
A Dimovski
A Dimovski
 and 
Lj Suturkova
Lj Suturkova
   | Mar 12, 2024
Balkan Journal of Medical Genetics's Cover Image
About this article
Previous Article
Next Article
Cite
Article Category: Original Article
Published Online: Mar 12, 2024
Page range: 35 - 40
DOI: https://doi.org/10.2478/bjmg-2023-0023
Keywords
© 2023 KA Nestorovska et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1.

Allelic distribution of ABCB1 and CYP2C19 in patients with CAD treated with clopidogrel
Allelic distribution of ABCB1 and CYP2C19 in patients with CAD treated with clopidogrel

Allelic distribution of the ABCB1 and CYP2C19 polymorphisms in CAD patients treated with clopidogrel

Allele Patients with positive outcome (N=52) Patients with negative outcome (N=44)
number of patients
CYP2C19*1/ ABCB1 C 36 34
CYP2C19*1/ ABCB1 T 37 28
CYP2C19*2/ ABCB1 C 11 14
CYP2C19*2/ ABCB1 T 11 16

Phenotype frequencies of CYP2C19 and ABCB1 in clopidogrel treated patients

Phenotype/Metabolizer Patients with positive outcome (N=52) Patients with negative outcome (N=44) OR p
N Observed Frequency (%) HWE Frequency (%) N Observed Frequency (%) HWE Frequency (%)
Normal* 9 0.1731 0.1872 2 0.0454 0.1673 1.000
Intermediate** 27 0.5192 0.4909 32 0.7272 0.4834 5.333 0.02805
Poor*** 16 0.3077 0.3218 10 0.2272 0.3491 2.812 0.22842

Demographic and clinical characteristics of the patients with coronary artery disease treated with clopidogrel.

Parameter Total number of patients (N=96) Patients with positive outcome (N=52) Patients with negative outcome (N=44)
Demographic characteristics
Age 60.42±9.05 60.64±9.19 60.16±9.22
Male 59 (61.46%) 33 (63.46%) 26 (59.09%)
Clinical characteristics
History of myocardial infarction 27 (28.13%) 10 (19.23%) 17 (38.64%)
History of diabetes 48 (50%) 24 (46.15) 24 (54.54%)
NYHA classification*
Class I 22 (22.92%) 15 (28.85%) 7 (15.91%)
Class II 31 (32.29%) 14 (26.92%) 17 (38.64%)
Class III 41 (42.71%) 22 (42.31%) 19 (43.18%)
Class IV 2 (2.08) 1 (1.92%) 1 (2.27%)
Diagnosis**
105–06 4 (4.17%) 3 (5.77%) 1 (2.27%)
120–23 54 (56.25%) 32 (61.54%) 22 (50%)
125 17 (17.71%) 8 (15.38%) 9 (20.45%)
135 3 (3.13%) 1 (1.92%) 3 (6.82%)
165–66, 170–74 17 (17.71%) 8 (15.38%) 9 (20.45%)

Genotype frequencies of ABCB1 and CYP2C19 in patients treated with clopidogrel

CYP2C19 ABCB1 Positive outcome N=52 Observed Frequency (%) HWE Frequency (%) Negative outcome N=44 Frequencies (%) Expected Frequencies (%) OR 95% p value
Genotype
ABCB1 CC homozygotes
*1/*1 CC 9 17.31 17.7 11 4.84 5.4 1.00
*1/*2 CC 3 5.77 5.0 2 4.55 3.4 0.545 0.074–4.008 0.54819
*2/*2 CC 0 0 0.4 0 0 0.6 0.826 0.015–45.693 1.0000
ABCB1 CT heterozygotes
*1/*1 CT 19 36.54 32.9 11 25 11.1 1.00
*1/*2 CT 5 9.62 16.8 10 22.73 9.7 3.455 0.936–12.743 0.05722
*2/*2 CT 3 5.77 2.2 2 4.55 2.1 1.152 0.166–7.990 0.88644
ABCB1 TT homozygotes
*1/*1 TT 10 19.23 19.6 4 9.09 8.6 1.00
*1/*2 TT 3 5.77 5.1 3 6.82 7.8 2.500 0.346–18.039 0.35720
*2/*2 TT 0 0 0.3 1 2.27 1.8 7.00 0.237–206.784 0.14323
eISSN:
1311-0160
Language:
English
Publication timeframe:
2 times per year
Journal Subjects:
Medicine, Basic Medical Science, other
Journal RSS Feed